9926.HK
Price:
$108.3
Market Cap:
$88.68B
Akeso, Inc., a biopharmaceutical company, researches, develops, manufactures, and commercializes therapies. The company develops AK104, a PD-1/CTLA-4 bi-specific antibody to treat cervical cancer, gastric cancer (GC), gastroesophageal junction (GEJ) adenocarcinoma, hepatocellular carcinoma (HCC), non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), nasopharyngeal carcinoma (NPC), clear cell renal cell carcinoma, and solid tumors; and AK112, a PD-1/VEGF bi-specific antibody to treat solid and gynecological tumors, NSCLC, SCLC, and triple-negative breast cancer (TNBC). It is also developing AK105, a PD-1 monoclonal antibody to treat NSCLC, NPC, classic Hodgkin's lymphoma (R/R cHL...[Read more]
Industry
Biotechnology
IPO Date
2020-04-24
Stock Exchange
HKSE
Ticker
9926.HK
According to Akeso, Inc.’s latest financial reports and current stock price. The company's current ROE is -8.55%. This represents a change of -231.28% compared to the average of 6.51% of the last 4 quarters.
The mean historical ROE of Akeso, Inc. over the last ten years is 618.31%. The current -8.55% ROE has changed -101.38% with respect to the historical average. Over the past ten years (40 quarters), 9926.HK's ROE was at its highest in in the December 2019 quarter at 2.40%. The ROE was at its lowest in in the June 2019 quarter at -24.00%.
Average
618.31%
Median
-31.74%
Minimum
-44.33%
Maximum
4.44%
Discovering the peaks and valleys of Akeso, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 30.49%
Maximum Annual ROE = 4.44%
Minimum Annual Increase = -14072.12%
Minimum Annual ROE = -44.33%
Year | ROE | Change |
---|---|---|
2024 | -7.55% | -117.47% |
2023 | 43.23% | -197.51% |
2022 | -44.33% | 30.49% |
2021 | -33.97% | 4.43% |
2020 | -32.53% | -100.73% |
2019 | 4.44% | -14072.12% |
The current ROE of Akeso, Inc. (9926.HK) is greater than its 3-year, greater than its 5-year, and less than than its 10-year historical averages
3-year avg
-2.89%
5-year avg
-15.03%
10-year avg
618.31%
Akeso, Inc.’s ROE is greater than Innovent Biologics, Inc. (-0.74%), greater than InnoCare Pharma Limited (-6.42%), greater than Peijia Medical Limited (-10.77%), greater than BeiGene, Ltd. (-11.51%), less than Alphamab Oncology (9.61%),
Company | ROE | Market cap |
---|---|---|
-0.74% | $132.54B | |
-6.42% | $21.69B | |
-10.77% | $4.71B | |
-11.51% | $217.71B | |
9.61% | $6.30B |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Akeso, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Akeso, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Akeso, Inc.'s ROE?
How is the ROE calculated for Akeso, Inc. (9926.HK)?
What is the highest ROE for Akeso, Inc. (9926.HK)?
What is the 3-year average ROE for Akeso, Inc. (9926.HK)?
What is the 5-year average ROE for Akeso, Inc. (9926.HK)?
How does the current ROE for Akeso, Inc. (9926.HK) compare to its historical average?